The interplay between host and viral factors in shaping the outcome of cytomegalovirus infection

Immunology and Cell Biology

Volumn 85, Issue 1, 2007, Pages 46-54

  Scalzo, Anthony A ^a,b   Corbett, Alexandra J ^a,b   Rawlinson, William D ^c   Scott, Gillian M ^c   Degli Esposti, Mariapia A ^a,b  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b LIONS EYE INSTITUTE   (Australia)

^c PRINCE OF WALES HOSPITAL   (Australia)

Author keywords

CTL; Cytomegalovirus; Genetic variability; Immune evasion; NK cells; Viral infection

Indexed keywords

ANTIVIRUS AGENT; CIDOFOVIR; DNA POLYMERASE; FOSCARNET; GANCICLOVIR; INTERFERON; LIGAND; NATURAL KILLER CELL RECEPTOR; PROTEIN KINASE;

CELL FUNCTION; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; CYTOTOXIC T LYMPHOCYTE; DISEASE COURSE; DISEASE MODEL; DOSE RESPONSE; DRUG RESPONSE; GENE CONTROL; GENE LOCUS; GENETIC VARIABILITY; GENOTYPE; HOST; HOST RESISTANCE; HUMAN; HUMAN CYTOMEGALOVIRUS; IMMATURITY; IMMUNE DEFICIENCY; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNOBIOLOGY; IMMUNOGENETICS; IN VIVO STUDY; MORBIDITY; MORTALITY; NATURAL KILLER CELL; NONHUMAN; PERSISTENT VIRUS INFECTION; PROTEIN PROTEIN INTERACTION; REVIEW; SPECIES DIFFERENCE; VIRUS CELL INTERACTION; VIRUS GENE; VIRUS IMMUNITY; VIRUS RESISTANCE; VIRUS SURVIVAL;

ANTIVIRAL AGENTS; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; DRUG RESISTANCE, VIRAL; GENES, VIRAL; GENOTYPE; HOST-PARASITE RELATIONS; HUMANS; VARIATION (GENETICS);

ANIMALIA; CYTOMEGALOVIRUS; HUMAN HERPESVIRUS 5; MAIZE CHLOROTIC MOTTLE VIRUS; MURINAE;

EID: 33846059092     PISSN: 08189641     EISSN: 14401711     Source Type: Journal    
DOI: 10.1038/sj.icb.7100013     Document Type: Review

References (122)

1. Chalmer JE, Mackenzie JS, Stanley NF. Resistance to murine cytomegalovirus linked to the major histocompatibility complex of the mouse. J Gen Virol 1977; 37: 107-114.
2. Selgrade MK, Osborn JE. Role of macrophages in resistance to murine cytomegalovirus. Infect Immun 1974; 10: 1383-1390.
3. Grundy (Chalmer) JE, Mackenzie JS, Stanley NF. Influence of H-2 and non-H-2 genes on resistance to murine cytomegalovirus infection. Infect Immun 1981; 32: 277-286.
4. Price P, Winter JG, Nikoletti S, Hudson JB, Shellam GR. Functional changes in murine macrophages infected with cytomegalovirus relate to H-2-determined sensitivity to infection. J Virol 1987; 61: 3602-3606.
5. Price P, Gibbons AE, Shellam GR. H-2 class I loci determine sensitivity to MCMV in macrophages and fibroblasts. Immunogenetics 1990; 32: 20-26.
6. Wykes MN, Shellam GR, McCluskey J, Kast WM, Dallas PB, Price P. Murine cytomegalovirus interacts with major histocompatibility complex class I molecules to establish cellular infection. J Virol 1993; 67: 4182-4189.
7. 2-microglobulin-deficient mice. J Immunol 1995; 154: 780-789.
8. Polic B, Jonjic S, Pavic I, Crnkovic I, Zorica I, Hengel H et al. Lack of MHC class I complex expression has no effect on spread and control of cytomegalovirus infection in vivo. J Gen Virol 1996; 77: 217-225.
9. Harnett GB, Shellam GR. Variation in murine cytomegalovirus replication in fibroblasts from different mouse strains in vitro: correlation with in vivo resistance. J Gen Virol 1982; 62: 39-47.
10. Desrosiers MP, Kielczewska A, Loredo-Osti JC, Adam SG, Makrigiannis AP, Lemieux S et al. Epistasis between mouse Klra and major histocompatibility complex class I loci is associated with a new mechanism of natural killer cell-mediated innate resistance to cytomegalovirus infection. Nat Genet 2005; 37: 593-599.
11. k role in NK cell-mediated resistance in acute murine cytomegalovirus-infected MA/My mice. J Immunol 2005; 175: 6820-6828.
12. Biron CA. Initial and innate responses to viral infections - pattern setting in immunity or disease. Curr Opin Microbiol 1999; 2: 374-381.
13. Grundy (Chalmer) JE, Trapman J, Allan JE, Shellam GR, Melief CJM. Evidence for a protective role of interferon in resistance to murine cytomegalovirus and its control by non-H-2-linked genes. Infect Immun 1982; 37: 143-150.
14. Dalod M, Salazar-Mather TP, Malmgaard L, Lewis C, Asselin-Paturel C, Briere F et al. Interferon alpha/beta and interleukin 12 responses to viral infections: pathways regulating dendritic cell cytokine expression in vivo. J Exp Med 2002; 195: 517-528.
15. Bukowski JF, Warner JF, Dennert G, Welsh RM. Adoptive transfer studies demonstrating the antiviral effect of natural killer cells in vivo. J Exp Med 1985; 161: 40-52.
16. Bukowski JF, Woda BA, Welsh RM. Pathogenesis of murine cytomegalovirus infection in natural killer cell-depleted mice. J Virol 1984; 52: 119-128.
17. Bancroft GJ, Shellam GR, Chalmer JE. Genetic influences on the augmentation of natural killer (NK) cells during murine cytomegalovirus infection: correlation with patterns of resistance. J Immunol 1981; 126: 988-994.
18. Scalzo AA, Fitzgerald NA, Simmons A, La Vista AB, Shellam GR. Cmv-1, a genetic locus that controls murine cytomegalovirus replication in the spleen. J Exp Med 1990; 171: 1469-1483.
19. Scalzo AA, Fitzgerald NA, Wallace CR, Gibbons AE, Smart YC, Burton RC et al. The effect of the Cmv-1 resistance gene, which is linked to the natural killer cell gene complex, is mediated by natural killer cells. J Immunol 1992; 149: 581-589.
20. Brown MG, Dokun AO, Heusel JW, Smith HRC, Beckman DL, Blattenberger EA et al. Vital involvement of a natural killer cell activation receptor in resistance to viral infection. Science 2001; 292: 934-937.
21. Daniels KA, Devora G, Lai WC, O'Donnell CL, Bennett M, Welsh RM. Murine cytomegalovirus is regulated by a discrete subset of natural killer cells reactive with monoclonal antibody to Ly49H. J Exp Med 2001; 194: 29-44.
22. Lee SH, Girard S, Macina D, Busa M, Zafer A, Belouchi A et al. Susceptibility to mouse cytomegalovirus is associated with deletion of an activating natural killer cell receptor of the C-type lectin superfamily. Nat Genet 2001; 28: 42-45.
23. Gosselin P, Mason LH, Willette-Brown J, Ortaldo JR, McVicar DW, Anderson SK. Induction of DAP12 phosphorylation, calcium mobilization and cytokine secretion by Ly49H. J Leuk Biol 1999; 66: 165-171.
24. Smith KM, Wu J, Bakker AB, Phillips JH, Lanier LL. Ly-49D and Ly-49H associate with mouse DAP12 and form activating receptors. J Immunol 1998; 161: 7-10.
25. Lee SH, Zafer A, de Repentigny Y, Kothary R, Tremblay ML, Gros P et al. Transgenic expression of the activating natural killer receptor Ly49H confers resistance to cytomegalovirus in genetically susceptible mice. J Exp Med 2003; 197: 515-526.
26. Sjolin H, Tomasello E, Mousavi-Jazi M, Bartolazzi A, Karre K, Vivier E et al. Pivotal role of KARAP/DAP12 adaptor molecule in the natural killer cell-mediated resistance to murine cytomegalovirus infection. J Exp Med 2002; 195: 825-834.
27. Arase H, Mocarski ES, Campbell AE, Hill AB, Lanier LL. Direct recognition of cytomegalovirus by activating and inhibitory NK cell receptors. Science 2002; 296: 1323-1326.
28. Smith HR, Heusel JW, Mehta IK, Kim S, Dorner BG, Naidenko OV et al. Recognition of a virus-encoded ligand by a natural killer cell activation receptor. Proc Natl Acad Sci USA 2002; 99: 8826-8831.
29. Bubić I, Wagner M, Krmpotić A, Saulig T, Kim S, Yokoyama WM et al. Gain of virulence caused by loss of a gene in murine cytomegalovirus. J Virol 2004; 78: 7536-7544.
30. Tripathy SK, Smith HR, Holroyd EA, Pingel JT, Yokoyama WM. Expression of m157, a murine cytomegalovirus-encoded putative major histocompatibility class I (MHC-I)-like protein, is independent of viral regulation of host MHC-I. J Virol 2006; 80: 545-550.
31. Dokun AO, Kim S, Smith HRC, Kang HSP, Chu DT, Yokoyama WM. Specific and nonspecific NK cell activation during virus infection. Nature Immunol 2001; 2: 951-956.
32. Scalzo AA, Lyons PA, Fitzgerald NA, Forbes CA, Yokoyama WM, Shellam GR. Genetic mapping of Cmv1 in the region of mouse chromosome 6 encoding the NK gene complex-associated loci Ly49 and musNKR-P1. Genomics 1995; 27: 435-441.
33. Anderson SK, Dewar K, Goulet ML, Leveque G, Makrigiannis AP. Complete elucidation of a minimal class I MHC natural killer cell receptor haplotype. Genes Immun 2005; 6: 481-492.
34. Brown MG, Scalzo AA, Stone LR, Clark PY, Du Y, Palanca B et al. Natural killer gene complex (Nkc) allelic variability in inbred mice: evidence for Nkc haplotypes. Immunogenetics 2001; 53: 584-591.
35. Lee SH, Gitas J, Zafer A, Lepage P, Hudson TJ, Belouchi A et al. Haplotype mapping indicates two independent origins for the Cmv1(s) susceptibility allele to cytomegalovirus infection and refines its localization within the Ly49 cluster. Immunogenetics 2001; 53: 501-505.
36. Scalzo AA, Manzur M, Forbes CA, Brown MG, Shellam GR. NK gene complex haplotype variability and host resistance alleles to murine cytomegalovirus in wild mouse populations. Immunol Cell Biol 2005; 83: 144-149.
37. Rodriguez M, Sabastian P, Clark P, Brown MG. Cmv1-independent antiviral role of NK cells revealed in murine cytomegalovirus-infected New Zealand white mice. J Immunol 2004; 173: 6312-6318.
38. Adam SG, Caraux A, Fodil-Cornu N, Loredo-Osti JC, Lesjean-Pottier S, Jaubert J et al. Cmv4, a new locus linked to the NK cell gene complex, controls innate resistance to cytomegalovirus in wild-derived mice. J Immunol 2006; 176: 5478-5485.
39. Beutler B, Crozat K, Koziol JA, Georgel P. Genetic dissection of innate immunity to infection: the mouse cytomegalovirus model. Curr Opin Immunol 2005; 17: 36-43.
40. Tabeta K, Georgel P, Janssen E, Du X, Hoebe K, Crozat K et al. Toll-like receptors 9 and 3 as essential components of innate immune defense against mouse cytomegalovirus infection. Proc Natl Acad Sci USA 2004; 101: 3516-3521.
41. Crozat K, Georgel P, Rutschmann S, Mann N, Du X, Hoebe K et al. Analysis of the MCMV resistome by ENU mutagenesis. Mamm Genome 2006; 17: 398-406.
42. Steinman RM. Some interfaces of dendritic cell biology. Apmis 2003; 111: 675-697.
43. Degli-Esposti MA, Smyth MJ. Close encounters of different kinds: dendritic cells and NK cells take centre stage. Nat Rev Immunol 2005; 5: 112-124.
44. Andrews DM, Andoniou CE, Granucci F, Ricciardi-Castagnoli P, Degli-Esposti MA. Infection of dendritic cells by murine cytomegalovirus induces functional paralysis. Nature Immunol 2001; 2: 1077-1084.
45. Andoniou CE, van Dommelen SL, Voigt V, Andrews DM, Brizard G, Asselin-Paturel C et al. Interaction between conventional dendritic cells and natural killer cells is integral to the activation of effective antiviral immunity. Nature Immunol 2005; 6: 1011-1019.
46. Mathys S, Schroeder T, Ellwart J, Koszinowski UH, Messerle M, Just U. Dendritic cells under influence of mouse cytomegalovirus have a physiologic dual role: to initiate and to restrict T cell activation. J Infect Dis 2003; 187: 988-999.
47. Andrews DM, Scalzo AA, Yokoyama WM, Smyth MJ, Degli-Esposti MA. Functional interactions between dendritic cells and NK cells during viral infection. Nature Immunol 2003; 4: 175-181.
48. Shortman K, Liu YJ. Mouse and human dendritic cell subtypes. Nat Rev Immunol 2002; 2: 151-161.
49. Belz GT, Smith CM, Eichner D, Shortman K, Karupiah G, Carbone FR et al. Conventional CD8-alpha+ dendritic cells are generally involved in priming CTL immunity to viruses. J Immunol 2004; 172: 1996-2000.
50. Pignatelli S, Dal Monte P, Rossini G, Landini MP. Genetic polymorphisms among human cytomegalovirus (HCMV) wild-type strains. Rev Med Virol 2004; 14: 383-410.
51. Redwood AJ, Messerle M, Harvey NL, Hardy CM, Koszinowski UH, Lawson MA et al. Use of a murine cytomegalovirus K181-derived bacterial artificial chromosome as a vaccine vector for immunocontraception. J Virol 2005; 79: 2998-3008.
52. Wagner M, Jonjic S, Koszinowski UH, Messerle M. Systematic excision of vector sequences from the BAC-cloned herpesvirus genome during virus reconstitution. J Virol 1999; 73: 7056-7060.
53. Jordan MC, Takagi JL. Virulence characteristics of murine cytomegalovirus in cell and organ cultures. Infect Immun 1983; 41: 841-843.
54. Selgrade MK, Nedrud JG, Collier AM, Gardner DE. Effects of cell source, mouse strain, and immunosuppressive treatment on production of virulent and attenuated murine cytomegalovirus. Infect Immun 1981; 33: 840-847.
55. Delale T, Paquin A, Asselin-Paturel C, Dalod M, Brizard G, Bates EE et al. MyD88-dependent and -independent murine cytomegalovirus sensing for IFN-alpha release and initiation of immune responses in vivo. J Immunol 2005; 175: 6723-6732.
56. Krug A, French AR, Barchet W, Fischer JA, Dzionek A, Pingel JT et al. TLR9-dependent recognition of MCMV by IPC and DC generates coordinated cytokine responses that activate antiviral NK cell function. Immunity 2004; 21: 107-119.
57. Voigt V, Forbes CA, Tonkin JN, Degli-Esposti MA, Smith HR, Yokoyama WM et al. Murine cytomegalovirus m157 mutation and variation leads to immune evasion of natural killer cells. Proc Natl Acad Sci USA 2003; 100: 13483-13488.
58. French AR, Pingel JT, Kim S, Yang L, Yokoyama WM. Rapid emergence of escape mutants following infection with murine cytomegalovirus in immunodeficient mice. Clin Immunol 2005; 115: 61-69.
59. French AR, Pingel JT, Wagner M, Bubic I, Yang L, Kim S et al. Escape of mutant double-stranded DNA virus from innate immune control. Immunity 2004; 20: 747-756.
60. Cretney E, Degli-Esposti MA, Densley EH, Farrell HE, Davis-Poynter NJ, Smyth MJ. m144, a murine cytomegalovirus (MCMV)-encoded major histocompatibility complex class I homologue, confers tumor resistance to natural killer cell-mediated rejection. J Exp Med 1999; 190: 435-444.
61. Farrell HE, Vally H, Lynch DM, Fleming P, Shellam GR, Scalzo AA et al. Inhibition of natural killer cells by a cytomegalovirus MHC class I homologue in vivo. Nature 1997; 386: 510-514.
62. Hasan M, Krmpotic A, Ruzsics Z, Bubic I, Lenac T, Halenius A et al. Selective downregulation of the NKG2D ligand H60 by mouse cytomegalovirus m155 glycoprotein. J Virol 2005; 79: 2920-2930.
63. Krmpotić A, Busch DH, Bubić I, Gebhardt F, Hengel H, Hasan M et al. MCMV glycoprotein gp40 confers virus resistance to CD8+ T cells and NK cells in vivo. Nature Immunol 2002; 3: 529-535.
64. Krmpotic A, Hasan M, Loewendorf A, Saulig T, Halenius A, Lenac T et al. NK cell activation through the NKG2D ligand MULT-1 is selectively prevented by the glycoprotein encoded by mouse cytomegalovirus gene m145. J Exp Med 2005; 201: 211-220.
65. Lodoen M, Ogasawara K, Hamerman JA, Arase H, Houchins JP, Mocarski ES et al. NKG2D-mediated natural killer cell protection against cytomegalovirus is impaired by viral gp40 modulation of retinoic acid early inducible 1 gene molecules. J Exp Med 2003; 197: 1245-1253.
66. Lodoen MB, Abenes G, Umamoto S, Houchins JP, Liu F, Lanier LL. The cytomegalovirus m155 gene product subverts natural killer cell antiviral protection by disruption of H60-NKG2D interactions. J Exp Med 2004; 200: 1075-1081.
67. Smith LM, Shellam GR, Redwood AJ. Genes of murine cytomegalovirus exist as a number of distinct genotypes. Virology 2006; 352: 450-465.
68. Beck S, Barrell BG. Human cytomegalovirus encodes a glycoprotein homologous to MHC class-I antigens. Nature 1988; 331: 269-272.
69. Browne H, Smith G, Beck S, Minson T. A complex between the MHC class I homologue encoded by human cytomegalovirus and b2 microglobulin. Nature 1990; 347: 770-772.
70. Fahnestock ML, Johnson JL, Feldman RMR, Neveu JM, Lane WS, Bjorkman PJ. The MHC class I homolog encoded by human cytomegalovirus binds endogenous peptides. Immunity 1995; 3: 583-590.
71. Leong CC, Chapman TL, Bjorkman PJ, Formankova D, Mocarski ES, Phillips JH et al. Modulation of natural killer cell cytotoxicity in human cytomegalovirus infection - the role of endogenous class i major histocompatibility complex and a viral class I homolog. J Exp Med 1998; 187: 1681-1687.
72. Reyburn HT, Mandelboim O, Vales-Gomez M, Davis DM, Pazmany L, Strominger JL. The class I MHC homologue of human cytomegalovirus inhibits attack by natural killer cells. Nature 1997; 386: 514-517.
73. Saverino D, Ghiotto F, Merlo A, Bruno S, Battini L, Occhino M et al. Specific recognition of the viral protein UL18 by CD85j/LIR-1/ILT2 on CD8+ T cells mediates the non-MHC-restricted lysis of human cytomegalovirus- infected cells. J Immunol 2004; 172: 5629-5637.
74. Vitale M, Castriconi R, Parolini S, Pende D, Hsu ML, Moretta L et al. The leukocyte Ig-like receptor (LIR)-1 for the cytomegalovirus UL18 protein displays a broad specificity for different HLA class I alleles: analysis of LIR-1(+) NK cell clones. Int Immunol 1999; 11: 29-35.
75. Cosman D, Fanger N, Borges L. Human cytomegalovirus, MHC class I and inhibitory signalling receptors: more questions than answers. Immunol Rev 1999; 168: 177-185.
76. Cerboni C, Achour A, Warnmark A, Mousavi-Jazi M, Sandalova T, Hsu ML et al. Spontaneous mutations in the human CMV HLA class I homologue UL18 affect its binding to the inhibitory receptor LIR-1/ILT2/CD85j. Eur J Immunol 2006; 36: 732-741.
77. Vales-Gomez M, Shiroishi M, Maenaka K, Reyburn HT. Genetic variability of the major histocompatibility complex class I homologue encoded by human cytomegalovirus leads to differential binding to the inhibitory receptor ILT2. J Virol 2005; 79: 2251-2260.
78. Del Val M, Schlicht H-J, Volkmer H, Messerle M, Reddehase MJ, Koszinowski UH. Protection against lethal cytomegalovirus infection by a recombinant vaccine containing a single nonameric T-cell epitope. J Virol 1991; 65: 3641-3646.
79. Del Val M, Volkmer H, Rothbard JB, Jonjic S, Messerle M, Schickedanz J et al. Molecular basis for cytolytic T-lymphocyte recognition of the murine cytomegalovirus immediate-early protein pp89. J Virol 1988; 62: 3965-3972.
80. Reddehase MJ, Rothbard JB, Koszinowski UH. A pentapeptide as minimal antigenic determinant for MHC class I-restricted T lymphocytes. Nature 1989; 337: 651-653.
81. Jonjic S, Del Val M, Keil GM, Reddehase MJ, Koszinowski UH. A nonstructural viral protein expressed by a recombinant vaccinia virus protects against lethal cytomegalovirus infection. J Virol 1988; 62: 1653-1658.
82. Lyons PA, Allan JE, Carrello C, Shellam GR, Scalzo AA. Effect of natural sequence variation at the H-2Ld-restricted CD8+ T cell epitope of the murine cytomegalovirus ie1-encoded pp89 on T cell recognition. J Gen Virol 1996; 77: 2615-2623.
83. Riddell SR, Rabin M, Geballe AP, Britt WJ, Greenberg PD. Class I MHC-restricted cytotoxic T lymphocyte recognition of cells infected with human cytomegalovirus does not require endogenous viral gene expression. J Immunol 1991; 146: 2795-2804.
84. Wills MR, Carmichael AJ, Mynard K, Jin X, Weekes MP, Plachter B et al. The human cytotoxic T-lymphocyte (CTL) response to cytomegalovirus is dominated by structural protein pp65: frequency, specificity and T-cell receptor usage of pp65-specific CTL. J Virol 1996; 70: 7569-7579.
85. Solache A, Morgan CL, Dodi AI, Morte C, Scott I, Baboonian C et al. Identification of three HLA-A*0201-restricted cytotoxic T cell epitopes in the cytomegalovirus protein pp65 that are conserved between eight strains of the virus. J Immunol 1999; 163: 5512-5518.
86. Gyulai Z, Endresz V, Burian K, Pincus S, Toldy J, Cox WI et al. Cytotoxic T lymphocyte (CTL) responses to human cytomegalovirus pp65, IE1-Exon4, gB, pp150, and pp28 in healthy individuals: reevaluation of prevalence of IE1-specific CTLs. J Infect Dis 2000; 181: 1537-1546.
87. Khan N, Cobbold M, Keenan R, Moss PA. Comparative analysis of CD8+ T cell responses against human cytomegalovirus proteins pp65 and immediate early 1 shows similarities in precursor frequency, oligoclonality, and phenotype. J Infect Dis 2002; 185: 1025-1034.
88. Prod'homme V, Retiere C, Valtcheva R, Bonneville M, Hallet MM. Cross-reactivity of HLA-B*1801-restricted T-lymphocyte clones with target cells expressing variants of the human cytomegalovirus 72kDa-IE1 protein. J Virol 2003; 77: 7139-7142.
89. Reusch U, Muranyi W, Lucin P, Burgert HG, Hengel H, Koszinowski UH. A cytomegalovirus glycoprotein re-routes MHC class I complexes to lysosomes for degradation. EMBO J 1999; 18: 1081-1091.
90. Ziegler H, Muranyi W, Burgert HG, Kremmer E, Koszinowski UH. The luminal part of the murine cytomegalovirus glycoprotein gp40 catalyzes the retention of MHC class I molecules. EMBO J 2000; 19: 870-881.
91. Ziegler H, Thale R, Lucin P, Muranyi W, Flohr T, Hengel H et al. A mouse cytomegalovirus glycoprotein retains MHC class I complexes in the ERGIC/cis-Golgi compartments. Immunity 1997; 6: 57-66.
92. Kavanagh DG, Koszinowski UH, Hill AB. The murine cytomegalovirus immune evasion protein m4/gp34 forms biochemically distinct complexes with class I MHC at the cell surface and in a pre-Golgi compartment. J Immunol 2001; 167: 3894-3902.
93. Kleijnen MF, Huppa JB, Lucin P, Mukherjee S, Farrell H, Campbell AE et al. A mouse cytomegalovirus glycoprotein, gp34, forms a complex with folded class I MHC molecules in the ER which is not retained but is transported to the cell surface. EMBO J 1997; 16: 685-694.
94. Kavanagh DG, Gold MC, Wagner M, Koszinowski UH, Hill AB. The multiple immune-evasion genes of murine cytomegalovirus are not redundant: m4 and m152 inhibit antigen presentation in a complementary and cooperative fashion. J Exp Med 2001; 194: 967-978.
95. Wagner M, Gutermann A, Podlech J, Reddehase MJ, Koszinowski UH. Major histocompatibility complex class I allele-specific cooperative and competitive interactions between immune evasion proteins of cytomegalovirus. J Exp Med 2002; 196: 805-816.
96. Holtappels R, Grzimek NK, Simon CO, Thomas D, Dreis D, Reddehase MJ. Processing and presentation of murine cytomegalovirus pORFm164-derived peptide in fibroblasts in the face of all viral immunosubversive early gene functions. J Virol 2002; 76: 6044-6053.
97. Holtappels R, Thomas D, Podlech J, Geginat G, Steffens HP, Reddehase MJ. The putative natural killer decoy early gene m04 (gp34) of murine cytomegalovirus encodes an antigenic peptide recognized by protective antiviral CD8T cells. J Virol 2000; 74: 1871-1884.
98. Holtappels R, Gillert-Marien D, Thomas D, Podlech J, Deegen P, Herter S et al. Cytomegalovirus encodes a positive regulator of antigen presentation. J Virol 2006; 80: 7613-7624.
99. Gold MC, Munks MW, Wagner M, McMahon CW, Kelly A, Kavanagh DG et al. Murine cytomegalovirus interference with antigen presentation has little effect on the size or the effector memory phenotype of the CD8 T cell response. J Immunol 2004; 172: 6944-6953.
100. Colletti KS, Xu Y, Cei SA, Tarrant M, Pari GS. Human cytomegalovirus UL84 oligomerization and heterodimerization domains act as transdominant inhibitors of oriLyt-dependent DNA replication: evidence that IE2-UL84 and UL84-UL84 interactions are required for lytic DNA replication. J Virol 2004; 78: 9203-9214.
101. Pari GS, Anders DG. Eleven loci encoding trans-acting factors are required for transient complementation of human cytomegalovirus oriLyt-dependent DNA replication. J Virol 1993; 67: 6979-6988.
102. Xu Y, Cei SA, Huete AR, Pari GS. Human cytomegalovirus UL84 insertion mutant defective for viral DNA synthesis and growth. J Virol 2004; 78: 10360-10369.
103. De Clercq E. Antiviral drugs: current state of the art. J Clin Virol 2001; 22: 73-89.
104. Littler E, Stuart AD, Chee MS. Human cytomegalovirus UL97 open reading frame encodes a protein that phosphorylates the antiviral nucleoside analogue ganciclovir. Nature 1992; 358: 160-162.
105. Sullivan V, Talarico CL, Stanat SC, Davis M, Coen DM, Biron KK. A protein kinase homologue controls phosphorylation of ganciclovir in human Cytomegalovirus-Infected cells. Nature 1992; 358: 162-164.
106. Chou S, Erice A, Jordan MC, Vercellotti GM, Michels KR, Talarico CL et al. Analysis of the UL97 phosphotransferase coding sequence in clinical cytomegalovirus isolates and identification of mutations conferring ganciclovir resistance. J Infect Dis 1995; 171: 576-583.
107. Chou S, Lurain NS, Weinberg A, Cai GY, Sharma PL, Crumpacker CS. Interstrain variation in the human cytomegalovirus DNA polymerase sequence and its effect on genotypic diagnosis of antiviral drug resistance. Adult AIDS clinical trials group CMV laboratories. Antimicrob Agents Chemother 1999; 43: 1500-1502.
108. Fillet AM, Auray L, Alain S, Gourlain K, Imbert BM, Najioullah F et al. Natural polymorphism of cytomegalovirus DNA polymerase lies in two nonconserved regions located between domains delta-C and II and between domains III and I. Antimicrob Agents Chemother 2004; 48: 1865-1868.
109. Alain S, Hantz S, Scieux C, Karras A, Mazeron MC, Szelag JC et al. Detection of ganciclovir resistance after valacyclovir-prophylaxis in renal transplant recipients with active cytomegalovirus infection. J Med Virol 2004; 73: 566-573.
110. Chou S. Antiviral drug resistance in human cytomegalovirus. Transpl Infect Dis 1999; 1: 105-114.
111. Gilbert C, Boivin G. Human cytomegalovirus resistance to antiviral drugs. Antimicrob Agents Chemother 2005; 49: 873-883.
112. Scott GM, Isaacs MA, Zeng F, Kesson AM, Rawlinson WD. Cytomegalovirus antiviral resistance associated with treatment induced UL97 (protein kinase) and UL54 (DNA polymerase) mutations. J Med Virol 2004; 74: 85-93.
113. Scott GM, Ng HL, Morton CJ, Parker MW, Rawlinson WD. Murine cytomegalovirus resistant to antivirals has genetic correlates with human cytomegalovirus. J Gen Virol 2005; 86: 2141-2151.
114. Emery VC, Griffiths PD. Prediction of cytomegalovirus load and resistance patterns after antiviral chemotherapy. Proc Natl Acad Sci USA 2000; 97: 8039-8044.
115. Emery VC, Hassan-Walker AF, Burroughs AK, Griffiths PD. Human cytomegalovirus (HCMV) replication dynamics in HCMV-naive and -experienced immunocompromised hosts. J Infect Dis 2002; 185: 1723-1728.
116. Emery VC. Investigation of CMV disease in immunocompromised patients. J Clin Pathol 2001; 54: 84-88.
117. Tchesnokov EP, Gilbert C, Boivin G, Gotte M. Role of helix P of the human cytomegalovirus DNA polymerase in resistance and hypersusceptibility to the antiviral drug foscarnet. J Virol 2006; 80: 1440-1450.
118. Ye LB, Huang ES. In vitro expression of the human cytomegalovirus DNA polymerase gene: effects of sequence alterations on enzyme activity. J Virol 1993; 67: 6339-6347.
119. Baldanti F, Underwood MR, Stanat SC, Biron KK, Chou S, Sarasini A et al. Single amino acid changes in the DNA polymerase confer foscarnet resistance and slow-growth phenotype, while mutations in the UL97-encoded phosphotransferase confer ganciclovir resistance in three double-resistant human cytomegalovirus strains recovered from patients with AIDS. J Virol 1996; 70: 1390-1395.
120. Cihlar T, Fuller MD, Mulato AS, Cherrington JM. A point mutation in the human cytomegalovirus DNA polymerase gene selected in vitro by cidofovir confers a slow replication phenotype in cell culture. Virology 1998; 248: 382-393.
121. Scott GM, Weinberg A, Rawlinson WD, Chou S. Multidrug resistance conferred by novel DNA polymerase mutations in human cytomegalovirus isolates. Antimicrob Agents Chemother 51(1): accepted 16 October 2006; doi:10.1128/AAC.00633-06.
122. Prichard MN, Gao N, Jairath S, Mulamba G, Krosky P, Coen DM et al. A recombinant human cytomegalovirus with a large deletion in UL97 has a severe replication deficiency. J Virol 1999; 73: 5663-5670.